Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018;391:1622–36. https://doi.org/10.1016/S0140-6736(18)30481-1.

Article  PubMed  Google Scholar 

Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of disease-modifying therapy in multiple sclerosis: should we stay or should we go? JAMA Neurol. 2021;78:787. https://doi.org/10.1001/jamaneurol.2021.0764.

Article  PubMed  Google Scholar 

Prosperini L, Lucchini M, Ruggieri S, et al. Shift of multiple sclerosis onset towards older age. J Neurol Neurosurg Psychiatry. 2022. https://doi.org/10.1136/jnnp-2022-329049.

Article  PubMed  Google Scholar 

Michelis D, Brunetti N, Solaro C, et al. Aging with multiple sclerosis: clinical characterization of an elderly population, a cross-sectional study. Mult Scler Relat Disord. 2023;69: 104464. https://doi.org/10.1016/j.msard.2022.104464.

Article  PubMed  Google Scholar 

Jakimovski D, Eckert SP, Zivadinov R, Weinstock-Guttman B. Considering patient age when treating multiple sclerosis across the adult lifespan. Expert Rev Neurother. 2021;21:353–64. https://doi.org/10.1080/14737175.2021.1886082.

Article  CAS  PubMed  Google Scholar 

Weideman AM, Tapia-Maltos MA, Johnson K, et al. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577. https://doi.org/10.3389/fneur.2017.00577.

Article  PubMed  PubMed Central  Google Scholar 

Grebenciucova E, Berger JR. Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis. Curr Neurol Neurosci Rep. 2017;17:61. https://doi.org/10.1007/s11910-017-0771-9.

Article  PubMed  Google Scholar 

Prosperini L, Haggiag S, Tortorella C, et al. Age-related adverse events of disease-modifying treatments for multiple sclerosis: a meta-regression. Mult Scler. 2021;27:1391–402. https://doi.org/10.1177/1352458520964778.

Article  CAS  PubMed  Google Scholar 

Jakimovski D, Vaughn CB, Eckert S, et al. Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opin Drug Saf. 2020;19:1121–42. https://doi.org/10.1080/14740338.2020.1805430.

Article  CAS  PubMed  Google Scholar 

Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:69–77. https://doi.org/10.1111/j.1468-1331.2010.03110.x.

Article  CAS  PubMed  Google Scholar 

Hartung H-P, Meuth SG, Miller DM, Comi G. Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis. Curr Opin Neurol. 2021;34:598–603. https://doi.org/10.1097/WCO.0000000000000960.

Article  PubMed  Google Scholar 

Prosperini L, Kinkel RP, Miravalle AA, et al. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809. https://doi.org/10.1177/1756286419837809.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:71. https://doi.org/10.1136/bmj.n71.

Article  Google Scholar 

O’Sullivan D, Wilk S, Michalowski W, Farion K. Using PICO to align medical evidence with MDs decision making models. Stud Health Technol Inform. 2013;192:1057.

PubMed  Google Scholar 

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5. https://doi.org/10.1007/s10654-010-9491-z.

Article  PubMed  Google Scholar 

Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97–111. https://doi.org/10.1002/jrsm.12.

Article  PubMed  Google Scholar 

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. https://doi.org/10.1002/sim.1186.

Article  PubMed  Google Scholar 

Berkovich R. Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report. Mult Scler Relat Disord. 2017;17:123–7. https://doi.org/10.1016/j.msard.2017.07.007.

Article  PubMed  Google Scholar 

Birnbaum G. Stopping disease-modifying therapy in nonrelapsing multiple sclerosis. Int J MS Care. 2017;19:11–4. https://doi.org/10.7224/1537-2073.2015-032.

Article  PubMed  PubMed Central  Google Scholar 

Bonenfant J, Bajeux E, Deburghgraeve V, et al. Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? Eur J Neurol. 2017;24:237–44. https://doi.org/10.1111/ene.13181.

Article  CAS  PubMed  Google Scholar 

Bsteh G, Hegen H, Riedl K, et al. Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: the VIAADISC score. Eur J Neurol. 2021;28:1609–16. https://doi.org/10.1111/ene.14705.

Article  PubMed  PubMed Central  Google Scholar 

Chappuis M, Rousseau C, Bajeux E, et al. Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis. J Neurol. 2023;270:413–22. https://doi.org/10.1007/s00415-022-11341-2.

Article  CAS  PubMed  Google Scholar 

Coerver EME, Bourass A, Wessels MHJ, et al. Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis. Mult Scler Relat Disord. 2023;74: 104706. https://doi.org/10.1016/j.msard.2023.104706.

Article  CAS  PubMed  Google Scholar 

Olival GS, Cavenaghi VB, Serafim V, et al. Medication withdrawal may be an option for a select group of patients in relapsing-remitting multiple sclerosis. Arq Neuropsiquiatr. 2013;71:516–20. https://doi.org/10.1590/0004-282X20130081.

Article  PubMed  Google Scholar 

Fagius J, Feresiadou A, Larsson E-M, Burman J. Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients: first line drugs vs natalizumab. Mult Scler Relat Disord. 2017;12:82–7. https://doi.org/10.1016/j.msard.2017.01.009.

Article  PubMed  Google Scholar 

Hua LH, Fan TH, Conway D, et al. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60. Mult Scler. 2019;25:699–708. https://doi.org/10.1177/1352458518765656.

Article  Google Scholar 

Jakimovski D, Kavak KS, Vaughn CB, et al. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age. Mult Scler Relat Disord. 2022;57: 103406. https://doi.org/10.1016/j.msard.2021.103406.

Article  CAS  PubMed  Google Scholar 

Kaminsky A-L, Omorou AY, Soudant M, et al. Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease inactivity. J Neurol. 2020;267:3518–27. https://doi.org/10.1007/s00415-020-10029-9.

Article  PubMed  Google Scholar 

Kister I, Spelman T, Alroughani R, et al. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry. 2016;87:1133–7. https://doi.org/10.1136/jnnp-2016-313760.

Article  PubMed  Google Scholar 

Landi D, Signori A, Cellerino M, et al. What happens after fingolimod discontinuation? A multicentre real-life experience. J Neurol. 2022;269:796–804. https://doi.org/10.1007/s00415-021-10658-8.

Article  CAS  PubMed  Google Scholar 

Lus G, Signoriello E, Maniscalco GT, et al. Treatment withdrawal in relapsing−remitting multiple sclerosis: a retrospective cohort study. Eur J Neurol. 2016;23:489–93. https://doi.org/10.1111/ene.12790.

Article  CAS  PubMed  Google Scholar 

McFaul D, Hakopian NN, Smith JB, et al. Defining benign/burnt-out MS and discontinuing disease-modifying therapies. Neurol Neuroimmunol Neuroinflammation. 2021;8: e960. https://doi.org/10.1212/NXI.0000000000000960.

Article  Google Scholar 

Monschein T, Salhofer-Polanyi S, Altmann P, et al. Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis. J Neurol. 2021;268:1247–53. https://doi.org/10.1007/s00415-020-10074-4.

Article  PubMed  Google Scholar 

Pasca M, Forci B, Mariottini A, et al. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;47: 102591. https://doi.org/10.1016/j.msard.2020.102591.

Article  CAS  PubMed  Google Scholar 

Salavisa M, Serrazina F, Ladeira AF, Correia AS. Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression. Clin Neurol Neurosurg. 2023;225: 107612. https://doi.org/10.1016/j.clineuro.2023.107612.

Article  PubMed  Google Scholar 

Siger M, Durko A, Nicpan A, et al. Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity. J Neurol Sci. 2011;303:50–2. https://doi.org/10.1016/j.jns.2011.01.016.

Article  PubMed  Google Scholar